TEDOR Pharma, Inc., a leading manufacturer of solid oral dose controlled formulations, announced the completion of their expansion of its large-scale manufacturing capacity, at its facility in Cumberland, Rhode Island.

The multi-million-dollar investment includes the installation of several multi-purpose cGMP bays and additional large-scale manufacturing equipment.  The new facilities will undergo validation and cGMP qualification prior to its operational startup slated for Q1 2017.  This enhanced capacity increases the large-scale manufacturing capabilities of the Cumberland facility, which supports client’s development projects from R&D through to large scale commercial manufacturing.

“Our facility in Rhode Island is adjacent to the 250 acres CVS corporate campus, which spans the town of Cumberland and the city of Woonsocket.  This investment is in response to our client’s demand for larger-scale, multi-purpose manufacturing capabilities,” commented Carl Wooten, CEO/President, Tedor Pharma.  “The manufacturing addition and investment in several technologies doubles our size, which will create expanded capacity and capabilities needed for our drug development programs.”

The expansion was just phase one of an ongoing strategic effort to invest in solid oral dose for both immediate release and modified release formulations, including schedule II controlled substances.

For more information contact Roger Martin at 401-658-5219 or rmartin@tedor.com.

Start typing and press Enter to search